دورية أكاديمية
أعرض في EDS

Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients.

التفاصيل البيبلوغرافية
العنوان: Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients.
المؤلفون: Cabrera NL; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., George IA, Rauseo AM, Mazi P, Spec A
المصدر: Current opinion in organ transplantation [Curr Opin Organ Transplant] 2022 Aug 01; Vol. 27 (4), pp. 235-242.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9717388 Publication Model: Print Cited Medium: Internet ISSN: 1531-7013 (Electronic) Linking ISSN: 10872418 NLM ISO Abbreviation: Curr Opin Organ Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Rapid Science Publishers,
مواضيع طبية MeSH: Mycoses*/diagnosis , Mycoses*/drug therapy , Mycoses*/microbiology , Invasive Fungal Infections*/diagnosis , Invasive Fungal Infections*/drug therapy , Organ Transplantation*/adverse effects, Humans ; Antifungal Agents/adverse effects ; Transplant Recipients
مستخلص: Purpose of Review: Recipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.
Recent Findings: These agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.
Summary: The properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12:220–229.
Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101–1111.
Schieffelin JS, Garcia-Diaz JB, Loss GE, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis 2014; 16:270–278.
Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis 2014; 16:578–587.
Klatt ME, Eschenauer GA. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. J Fungi (Basel) 2021; 7:76.
Bhagat V, Pandit RA, Ambapurkar S, et al. Drug interactions between antimicrobial and immunosuppressive agents in solid organ transplant recipients. Indian J Crit Care Med 2021; 25:67–76.
Gavaldà J, Meije Y, Fortún J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20:27–48.
Riat A, Plojoux J, Gindro K, et al. Azole resistance of environmental and clinical Aspergillus fumigatus isolates from Switzerland. Antimicrob Agents Chemother 2018; 62:e02088–e2117.
Meis JF, Chowdhary A, Rhodes JL, et al. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus . Philos Trans R Soc Lond B Biol Sci 2016; 371:20150460.
Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother 2011; 55:4652–4658.
Fu Y, Luo G, Spellberg BJ, et al. Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans . Eukaryot Cell 2008; 7:483–492.
Watanabe NA, Miyazaki M, Horii T, et al. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother 2012; 56:960–971.
Hodges MR, Ople E, Shaw KJ, et al. Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability. Open Forum Infectious Diseases 2017; 4: (Suppl_1): S534–S1534.
Pfaller MA, Hata K, Jones RN, et al. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011; 71:167–170.
Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris . Antimicrob Agents Chemother 2018; 62:e02319-17.
Arendrup MC, Chowdhary A, Astvad KMT, et al. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother 2018; 62:e01225-18.
Zhao M, Lepak AJ, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother 2018; 62:e02542–17.
Jørgensen KM, Astvad KMT, Arendrup MC. In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination. Antimicrob Agents Chemother 2020; 64:e00730-20.
Shaw KJ, Schell WA, Covel J, et al. In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus . Antimicrob Agents Chemother 2018; 62:e00523-18.
Viriyakosol S, Kapoor M, Okamoto S, et al. APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia. Antimicrob Agents Chemother 2019; 63:e01715-18.
Castanheira M, Duncanson FP, Diekema DJ, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother 2012; 56:352–357.
Pfaller MA, Duncanson F, Messer SA, et al. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 2011; 55:5155–5158.
Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother 2020; 64:e01735-19.
Dadwal, S., Winston, D.J., Bloch, K.C., et al . Fosmanogepix treatment for Fusarium infections in patients under an expanded access program: case series and review. In 31st European Congress of Clinical Microbiology and Infectious Diseases. 2021. Vienna, Austria.
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother 2019; 74:1295–1299.
Hodges MR, Ople E, Shaw KJ, et al. First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. Open Forum Infect Dis 2017; 4: (Suppl_1): S526–S1526.
Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi 2020; 6:239.
Sandison T, Ong V, Thye D. Safety and pharmacokinetics of CD101 Iv, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 2017; 61:e01627-16.
Krishnan BR, James KD, Polowy K, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot (Tokyo) 2017; 70:130–135.
Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother 2016; 60:6872–6879.
Zhao Y, Prideaux B, Nagasaki Y, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother 2017; 61:e01009-17.
Pfaller MA, Messer SA, Rhomberg PR, et al. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. Int J Antimicrob Agents 2017; 50:352–358.
Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother 2016; 71:2868–2873.
Arendrup MC, Meletiadis J, Zaragoza O, et al. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. Clin Microbiol Infect 2018; 24:1200–1204.
Lepak AJ, Zhao M, VasScoy B, et al. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother 2018; 62:e02154-17.
Hager CL, Larkin EL, Long LA, et al. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 2018; 73:2085–2088.
Wiederhold NP, Locke JB, Daruwala P, et al. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother 2018; 73:3063–3067.
Miesel L, Cushion MT, Ashbaugh A, et al. Efficacy of Rezafungin in prophylactic mouse models of invasive Candidiasis, Aspergillosis, and Pneumocystis pneumonia. Antimicrob Agents Chemother 2021; 65:e01992-20.
Nyirjesy P, Alessio C, Jandourek A, et al. CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial. J Low Genit Tract Dis 2019; 23:226–229.
Nyirjesy P, Jandourek A, Lee J, et al. Results from RADIANT, a phase 2, randomized, open-label, sponsor-blinded study of CD101 topical in patients with moderate-to-severe acute vulvovaginal candidiasis. Am J Obstet Gynecol 2017; 217:715.
Thompson GR III, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis 2020; 73:e3647–e3655.
Cidara Therapeutics, Inc. Cidara therapeutics and mundipharma announce positive topline results from global phase 3 pivotal, ReSTORE trial of rezafungin for the treatment of candidemia and invasive, candidiasis. 2021; http://ir.cidara.com/news-releases/news-release-details/cidara-therapeutics-and-mundipharma-announce-positive-toplinehttp://ir.cidara.com/news-releases/news-release-details/cidara-therapeutics-and-mundipharma-announce-positive-topline [Accessed 28 April 2022].
Wring SA, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother 2017; 61:e02068-16.
Pfaller MA, Messer SA, Motyl MR, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 2013; 68:858–863.
Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 2014; 58:1248–1251.
Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris : growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother 2017; 61:e02396-16.
Berkow EL, Angulo D, Lockhart SR. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris . Antimicrob Agents Chemother 2017; 61:e00435-17.
Pfaller MA, Messer SA, Rhomberg PR, et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother 2017; 61:e00161-17.
Wiederhold NP, Najvar LK, Jaramillo R, et al. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata . J Antimicrob Chemother 2018; 73:448–451.
Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 2013; 57:1065–1068.
Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 2015; 59:4308–4311.
Barat, S., Borroto-Esoda, K., Ashbaugh, A., et al. , Efficacy of ibrexafungerp (formerly SCY-078) against pneumocystis pneumonia in a murine therapeutic model, in European Conference of Clinical Microbiology and Infectious Diseases (ECCMID). 2019: Amsterdam, Netherlands.
Cushion, M., Ashbaugh, A., Borroto-Esoda, K., et al. , SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia, in European Conference of Clinical Microbiology and Infectious Diseases (ECCMID). 2018: Madrid, Spain.
Alexander BD, Cornely O, Pappas P, et al. 1248. Efficacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI). Open Forum Infect Dis 2020; 7: (Suppl_1): S642–S1642.
Spec A, Pullman J, Thompson GR, et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in nonneutropenic patients with invasive candidiasis. J Antimicrob Chemother 2019; 74:3056–3062.
Nyirjesy P, Schwebke JR, Angulo DA, et al. Phase 2 randomized study of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis. Clin Infect Dis 2021; ciab841.
Wring S, Murphy G, Atiee G, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug–drug interactions. J Clin Pharmacol 2018; 58:1305–1313.
Wring S, Murphy G, Atiee G, et al. Clinical pharmacokinetics and drug–drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev 2019; 8:60–69.
Lee A. Ibrexafungerp: first approval. Drugs 2021; 81:1445–1450.
Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303). Clin Infect Dis 2021; 74:1979–1985.
Sobel R, Nyirjesy P, Ghannoum MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). Bjog 2022; 129:412–420.
Cass L, Murray A, Davis A, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect 2021; 9:e00690.
Colley T, Alanio A, Kelly SL, et al. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection. Antimicrob Agents Chemother 2017; 61:e02280-16.
Cuddihy G, Wasan EK, Di Y, et al. The development of oral amphotericin B to treat systemic fungal and parasitic infections: has the myth been finally realized? Pharmaceutics 2019; 11:99.
Aigner M, Lass-Flörl C. Encochleated amphotericin B: is the oral availability of amphotericin B finally reached? J Fungi (Basel) 2020; 6:66.
Zarif L, Graybill JR, Perlin D, et al. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000; 44:1463–1469.
Mannino, R.J., and Perlin, D.S., Oral dosing of encochleated amphotericin B (CAmB): Rapid drug targeting to infected tissues in mice with systemic candidiasis, in Interscience Conference of Antimicrobial Agents and Chemotherapy. 2015: San Diego, California.
Santangelo R, Paderu P, Delmas G, et al. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000; 44:2356–2360.
Delmas G, Park S, Chen ZW, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002; 46:2704–2707.
Lu R, Hollingsworth C, Qiu J, et al. Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. mBio 2019; 10:e00724-19.
Wasan KM, Wasan EK, Gershkovich P, et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009; 200:357–360.
Skipper CP, Atukunda M, Stadelman A, et al. Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B. Antimicrob Agents Chemother 2020; 64:e00838–20.
Matinas BioPharma. Matinas BioPharma reports topline data from phase 2 clinical study of orally-administered MAT2203 for the treatment of vulvovaginal candidiasis. 2017. https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/294/matinas-biopharma-reports-topline-data-from-phase-2 [Accessed 28 April 2022].
Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A 2016; 113:12809–12814.
Law, D., Birch, M., Oliver, J., et al ., Pharmacokinetics of the novel antifungal agents F901318 in mice, rats and cynomolgus, in 55th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015: San Diego, CA.
Georgacopoulos O, Nunnally NS, Ransom EM, et al. In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents. J Fungi (Basel) 2021; 7:378.
Singh A, Singh P, Meis JF, et al. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother 2021; 76:1229–1233.
Su H, Zhu M, Tsui CK, et al. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China. Antimicrob Agents Chemother 2021; 65:e02546-20.
Astvad KMT, Jørgensen KM, Hare RK, et al. Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018–2019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother 2020; 65:e01527-20.
Jørgensen KM, Astvad KMT, Hare RK, et al. EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs. Antimicrob Agents Chemother 2018; 62:e00487-18.
Buil JB, Rijs A, Meis JF, et al. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J Antimicrob Chemother 2017; 72:2548–2552.
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother 2019; 74:1586–1590.
Lackner M, Birch M, Naschberger V, et al. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. J Antimicrob Chemother 2018; 73:3068–3073.
Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans , Exophiala dermatitidis and azole-resistant Aspergillus fumigatus . Int J Antimicrob Agents 2020; 56:106105.
Badali H, Cañete-Gibas C, Patterson H, et al. In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes. Mycoses 2021; 64:748–752.
Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med Mycol 2018; 56:1050–1054.
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother 2020; 75:3582–3585.
Wiederhold NP, Law D, Birch M. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans . J Antimicrob Chemother 2017; 72:1977–1980.
Zhang J, Liu H, Xi L, et al. Antifungal susceptibility profiles of olorofim (formerly F901318) and currently available systemic antifungals against mold and yeast phases of Talaromyces marneffei. Antimicrob Agents Chemother 2021; 65:e00256-21.
Kirchhoff L, Dittmer S, Furnica DT, et al. Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim. J Antimicrob Chemother 2022; 77:1645–1654.
Seyedmousavi S, Chang YC, Law D, et al. Efficacy of olorofim (F901318) against Aspergillus fumigatus , A. nidulans , and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob Agents Chemother 2019; 63:e00129-19.
Lim W, Eadie K, Konings M, et al. Madurella mycetomatis , the main causative agent of eumycetoma, is highly susceptible to olorofim. J Antimicrob Chemother 2020; 75:936–941.
Lim W, Nyuykonge B, Eadie K, et al. Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma. PLoS Negl Trop Dis 2022; 16:e0010159.
Mirbzadeh Ardakani E, Sharifirad A, Pashootan N, et al. Olorofim effectively eradicates dermatophytes in vitro and in vivo. Antimicrob Agents Chemother 2021; 65:e0138621.
Wiederhold NP, Najvar LK, Jaramillo R, et al. The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis. Antimicrob Agents Chemother 2018; 62:e00999-18.
المشرفين على المادة: 0 (Antifungal Agents)
تواريخ الأحداث: Date Created: 20221110 Date Completed: 20221111 Latest Revision: 20230203
رمز التحديث: 20240628
DOI: 10.1097/MOT.0000000000000995
PMID: 36354248
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7013
DOI:10.1097/MOT.0000000000000995